| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO
1 company
Kevin Koch is President and CEO at EWTX. Kevin Koch's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.0M at current prices.
Historically, Kevin Koch's trades have earned a middling insider score of 51/100 across 7 rated trades. Over a 12-month horizon, 42.9% of those trades were profitable, with an average 12-month return of -37.1%.
The EWTX filings lean toward selling, a net 46,210 shares.
Kevin Koch has 16 Form 4 filings on record from June 2017 to August 2026, across 2 companies: President and CEO at Edgewise Therapeutics (EWTX), 2021–2026; Director at Viridian Therapeutics, Inc.\DE (VRDN), 2017–2020.
The 33 reported transactions were 14 option or other derivative awards, 10 open-market sales and 9 option exercises.
Counted by filing, the open-market trades come to no purchases and 7 sales worth about $1.3M.
The largest open-market sale was 17,971 shares of EWTX at an average $43.68 on August 12, 2026, about $785K.
2 of the 7 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 5 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | EWTX Edgewise Therapeutics, Inc. | President and CEO | Sale+OE | 17,971 | $43.68 | $785,042.06 | -25.5% | - | - | |
| Aug 12, 2025 | EWTX Edgewise Therapeutics, Inc. | President and CEO | Sale+OE | 7,972 | $13.39 | $106,764.21 | -20.7% | +36.5% | +225.3% | |
| May 2, 2025 | EWTX Edgewise Therapeutics, Inc. | President and CEO | Sale+OE | 4,276 | $16.45 | $70,358.16 | -17.2% | -15.7% | +81.0% | |
| Mar 7, 2025 | EWTX Edgewise Therapeutics, Inc. | President and CEO | Sale+OE10b5-1 | 100 | $30.00 | $3,000.00 | -0.7% | -47.1% | -0.7% | |
| Feb 6, 2025 | EWTX Edgewise Therapeutics, Inc. | President and CEO | Sale+OE10b5-1 | 9,536 | $30.13 | $287,315.62 | -39.7% | -49.4% | +1.4% | |
| May 2, 2024 | EWTX Edgewise Therapeutics, Inc. | President and CEO | Sale+OE | 3,152 | $18.91 | $59,604.32 | -17.9% | -11.7% | -12.3% | |
| May 2, 2023 | EWTX Edgewise Therapeutics, Inc. | President and CEO | Sale+OE | 3,203 | $8.90 | $28,522.39 | -30.8% | -16.7% | +117.3% |